Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp235 | Cell biology: osteoclasts and bone resorption | ECTS2013

Differential effects of nitrogen-containing bisphosphonates on human PBMCs and MUTZ-3 cells

Kwaasi Aaron , Mabilleau Guillaume , Dunford James , Ebetino Frank , Zarei Ali , Pazianas Michael , Sabokbar Afsie , Russell Graham

Introduction: Nitrogen-containing bisphosphonates (N-BPs) can inhibit the differentiation and function of osteoclasts derived from Peripheral Blood Mononuclear cells (PBMCs) in a dose-dependent manner. MUTZ-3 cells are a potentially useful human cell line for studying osteoclast differentiation. The aim of this study was to elucidate the action of N-BPs on MUTZ-3 cells.Methods: Human PBMCs and MUTZ-3 cells were cultured in α-MEM supplemented with he...

ba0005p128 | Cancer and bone: basic, translational and clinical | ECTS2016

The pharmacological profile of a novel highly potent bisphosphonate, OX14 (1-fluoro-2-(imidazo-[1,2 alpha]pyridin-3-yl)ethyl-bisphosphonate), with reduced bone affinity, which is as effective as zoledronate in the treatment of myeloma bone disease in JJN3-NOD/SCID-γ mice

Lawson Michelle , Chantry Andrew , Paton-Hough Julia , Evans Holly , Lath Darren , Tsoumpra Maria , Lundy Mark , Dobson Roy , Quijano Michael , Kwaasi Aaron , Dunford James , Duan Xuchen , Triffit James , Mazur Adam , Jeans Gwyn , Russell Graham , Ebetino Hal

Bisphosphonates are used in the treatment of a variety of diseases with skeletal complications. With the development of more potent compounds, there is the potential for further improvement. One concept is to use compounds with a reduced affinity for bone, reducing their long-term retention and possible adverse events, as well as potentially enhancing their non-skeletal benefits. We hypothesise that a highly potent bisphosphonate with low bone affinity, known as OX14, will be ...